AZN vs IMNM: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AZN and IMNM share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AZN and IMNM exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

AstraZeneca is one of the world's largest biopharmaceutical companies, headquartered in Cambridge, England, with deep Anglo-Swedish roots. It develops and sells prescription medicines across four main areas: oncology (its biggest engine), cardiovascular-renal-metabolism, respiratory and immunology, and rare disease through Alexion, which it acquired in 2021. Flagship products include the cancer drugs Tagrisso, Imfinzi, Calquence, Lynparza (partnered with Merck) and Enhertu (partnered with Daiichi Sankyo), plus the diabetes and heart-failure drug Farxiga and rare-disease therapies like Ultomiris and Soliris. In 2025 the company reported total revenue of about $58.7 billion, up roughly 9%, and it has set a public ambition to grow that to $80 billion by 2030, with about half expected to come from the United States.

Full AZN guide

Immunome, Inc. is a Nasdaq-listed, clinical-stage targeted-oncology company developing cancer therapies. Its lead asset is varegacestat, a once-daily oral gamma secretase inhibitor for adults with progressing desmoid tumors; the company submitted a New Drug Application to the U.S. FDA in April 2026, backed by the Phase 3 RINGSIDE trial that showed an ~84% reduction in the risk of disease progression or death and a ~56% confirmed objective response rate versus ~9% for placebo. Behind that lead program sits an antibody-drug-conjugate (ADC) and radiotherapy pipeline, including IM-1021 (a ROR1 ADC), IM-3050 (a FAP-targeted radiotherapy), IM-1617, and additional preclinical candidates.

Full IMNM guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• AZN drivers: Oncology franchise and the $80 billion ambition; Deep late-stage pipeline.
• IMNM drivers: Varegacestat FDA decision and launch; ADC and radiotherapy pipeline.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The dominant risk is the patent cliff: from around 2032, Tagrisso, Imfinzi and Calquence are expected to begin losing exclusivity, a headwind analysts have sized at more than $20 billion, so the whole thesis hinges on the pipeline replacing that revenue in time. For IMNM, as a clinical-stage biotech, Immunome is exposed to substantial binary risk: the FDA could delay, restrict, or reject varegacestat, and any label or safety concern would materially reset the stock.

Pick AZN if you believe its drivers more; IMNM if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the AZN and IMNM guides.

AZN. Figures are approximate and tied to the asOf date; confirm live numbers before acting. AstraZeneca trades as a growth-oriented large-cap pharma, so its valuation reflects confidence in the pipeline delivering on the $80 billion 2030 goal more than any single current metric. A patent cliff early next decade means today's revenue base is not guaranteed to persist, so how you weigh future launches matters more than trailing multiples.

IMNM. Immunome trades on pipeline expectations, not profits, so conventional earnings multiples do not apply to a pre-commercial developer with minimal revenue and ongoing losses. Its roughly $2.6 billion market value largely reflects the market's probability-weighted view of varegacestat approval plus the ADC pipeline. The sizable cash balance funds operations into 2028 but does not by itself justify the valuation.

Headline figures (approximate, Jul 2026): AZN shows revenue (ttm) Around $60 billion; 2025 total revenue was about $58.7 billion, up roughly 9%, with Q1 2026 up about 8% at constant currency, growth drivers Oncology (Tagrisso, Imfinzi, Calquence, Enhertu, Lynparza), rare disease (Ultomiris, Soliris) and metabolic launches; company ambition of $80 billion revenue by 2030, margins/profitability Solidly profitable large-cap pharma; heavy, sustained R&D spending funds the pipeline that the 2030 target depends on, dividend Pays a regular dividend; recent yield roughly 2%, modest for the sector but backed by large, growing cash flows; IMNM shows market cap ~$2.6B, share price ~$23, revenue (fy2025) ~$7M, cash & equivalents (mar 2026) ~$582.7M.

AZN and IMNM are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined AZN and IMNM exposure against your real portfolio. It is not an investment adviser.